The clarification follows the publication of information connected with the interview with LEO-Pharma

COPENHAGEN, Denmark | February 8, 2008 | TopoTarget A/S (OMX:TOPO today wishes to clarify the status of the company’s collaboration with LEO Pharma concerning a pre-clinical compound for investigation for the treatment of psoriasis.

The clarification follows thepublication of information connected with an interview with LEO Pharma, which appeared in the Danish news paper Børsentoday.

TopoTarget was informed on January 23 2008 that LEO Pharma planned to discontinue development of a very early stage pre- clinical compound originally in-licensed from TopoTarget for the treatment of psoriasis. Under the terms of the agreement the collaboration ends after athree month period on April302008.

During the termination period a report concerning the project will be sent toTopoTarget by LEOPharma.

TopoTarget wishes to state that information regarding pre-clinical programs within significant financial and strategic impact on the company are normally announced in the Quarterly report.

The HDACi (PXD118490/LEO80140 pre-clinical compoundwasout- licensed to LEO Pharma in 2006 for investigation for potential use in treating psoriasis. The compound will now revert toTopoTarget’s pre-clinical team where further development opportunities will be consididered. This compound was one out of around 800 compounds in TopoTarget’s pre-clinical library.

“Psoriasis is not a focus area for TopoTarget and this out-licensing agreement was part of our business development strategy to allow pharmaceutical companies to investigate interesting compounds in early stage development efforts to find new treatments.” Said Peter BuhlJensen, CEOofTopoTarget.

“TopoTarget is dedicated to finding treatments for cancer and the value of business is in our marketed product Savene®/Totect™ and in our robust clinical pipeline consisting of belinostat and 8 additional products in Phase I and Phase II clinical development.”
Today’s news does not change TopoTarget’s full-year financial guidance.

AboutTopoTarget

TopoTarget(OMX:TOPO)is a biotech company, headquartered in Denmark and with subsidiaries in the US, Switzerland, Germany and the UK, dedicated to finding' 'Answers for Cancer'' and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands -on clinical experience within-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer targets (including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors)and a strong development foundation has been built.TopoTarget has a broad portfolio of small molecule pre-clinical drug candidates and nine drugs(both small molecules and protein based)are in clinical development,including both novel anti-cancer therapeutics and new cancer indications for existing drugs.

SOURCE: TOPOTARGET

---